# Compare CJC-1295, GHK-Cu, Semaglutide & Tesamorelin — Peptide Scienes

> A side-by-side comparison of four Research Peptide Fundamentals research peptides — CJC-1295, GHK-Cu, semaglutide, and tesamorelin — across mechanism, evidence base, regulatory status, and key caution.

CJC-1295, GHK-Cu, semaglutide, and tesamorelin, lined up on the dimensions that actually determine how much confidence a claim about each one deserves.

## The short version

This page lines up [CJC-1295](/cjc-1295), [GHK-Cu](/ghk-cu), [semaglutide](/semaglutide), and [tesamorelin](/tesamorelin) on the dimensions that matter most when reading research-peptide claims: what receptor or pathway each one actually engages, what it has been studied for, how deep and how recent that evidence is, its current regulatory status, and the single caution most worth carrying away from each page. The headline finding is that "research peptide" hides enormous variation. Two of these four target the exact same receptor; one is a copper-binding molecule the body already makes; and only one has cleared broad FDA approval, while a second has cleared a narrow one and the remaining two have cleared none. None of this is medical advice, and no dose is recommended anywhere on this page.

## The comparison matrix

| Dimension | CJC-1295 | GHK-Cu | Semaglutide | Tesamorelin |
| --- | --- | --- | --- | --- |
| Peptide class | GHRH receptor agonist, long-acting (DAC) or short-acting variant | Copper-binding tripeptide (Gly-His-Lys + Cu2+) | GLP-1 receptor agonist (incretin mimetic) | GHRH receptor agonist, short-acting |
| Most studied in | GH/IGF-1 pharmacokinetics in healthy adults | Topical skin and hair regeneration (cosmetic) | Type 2 diabetes, obesity, cardiovascular and kidney outcomes | HIV-associated lipodystrophy (visceral fat) |
| Evidence base | Small early-phase human PK studies (n~11-50), no outcome trial [3][4][5] | Small controlled topical trials plus extensive cell/gene-expression data [6][7][12] | Large multi-thousand-participant RCTs across many indications [13][14][15][16] | FDA-reviewed pivotal RCTs plus a 2026 meta-analysis, one indication [18][20][22] |
| Regulatory status | Not approved anywhere; research chemical | Topical Copper Tripeptide-1 a legal cosmetic ingredient; systemic use unapproved | FDA-approved (multiple indications) | FDA-approved (HIV lipodystrophy only) |
| Key caution | No long-term human safety data behind a widely circulated set of anecdotal benefits [1] | Sharp split between well-documented topical use and essentially undocumented systemic use | GI intolerance, gallbladder risk, weight regain after stopping [17] | Benefit fades without continued use; scope limited to the studied population [22] |

## Peptide class and mechanism

Two of the four compounds here are, mechanistically, close relatives: CJC-1295 and tesamorelin are both growth-hormone-releasing hormone (GHRH) analogs that bind the same pituitary receptor and trigger the same signaling cascade, differing mainly in how long they stay active and in the regulatory path each has taken [1]. GHK-Cu is a fundamentally different kind of molecule — a naturally occurring copper-chelating tripeptide that works partly by delivering a reactive metal ion to tissue and partly through direct effects on gene expression, unrelated to hormone-receptor signaling [7][12]. Semaglutide is different again: an incretin mimetic that activates the GLP-1 receptor, a pathway involved in insulin release, appetite, and gut motility, with no structural or mechanistic overlap with the other three [13].

## Most-studied application

CJC-1295's published research is almost entirely pharmacokinetic — how much growth hormone and IGF-1 rise, and for how long, in healthy volunteers — rather than research into any specific health outcome [4][5]. GHK-Cu's deepest evidence sits in topical dermatology and hair-growth trials, benchmarked directly against established actives like vitamin C and retinoic acid [6][8]. Semaglutide's trial program is the broadest by far, spanning type 2 diabetes, chronic weight management, cardiovascular event reduction, and kidney-disease outcomes [14][15][16]. Tesamorelin's entire pivotal evidence base addresses one outcome in one population: visceral and hepatic fat reduction in HIV-associated lipodystrophy [18][20].

## Evidence base

This is where the four genuinely separate. Semaglutide has the deepest and most diverse human evidence: multi-thousand-participant randomized trials across several indications and years of real-world monitoring [14][15][16][17]. Tesamorelin's evidence is narrower but still rigorous — pivotal RCTs plus a 2026 meta-analysis, all within one patient population [18][20][22]. GHK-Cu's evidence is almost inverted: an enormous cell- and gene-expression literature paired with a comparatively small set of controlled human trials, concentrated in topical cosmetic use [7][9]. CJC-1295 has the thinnest human evidence of the four — a handful of short pharmacokinetic studies in healthy adults from the 2000s, with no trial testing any specific outcome [3][4][5].

## Regulatory status

Semaglutide and tesamorelin are both FDA-approved, but the breadth of approval differs enormously: semaglutide across several indications, tesamorelin for exactly one [19]. GHK-Cu occupies a split status — legal and widely used as a topical cosmetic ingredient, with no approved pathway for injectable or systemic use. CJC-1295 has no approved status anywhere and is treated, in FDA advisory-committee review, as a compound with unresolved immunogenicity questions rather than one ready for broader medical use [1].

## Key caution

For CJC-1295, it is the near-total absence of long-term human safety data behind a widely circulated set of anecdotal benefits. For GHK-Cu, it is the sharp split between well-documented topical use and essentially undocumented systemic use. For semaglutide, it is that gastrointestinal intolerance and gallbladder risk are real, quantified costs of an otherwise well-evidenced drug, and that its benefits reverse substantially if it is stopped [17]. For tesamorelin, it is scope: the trial evidence is solid, but it describes one population and one outcome, and the benefit itself fades within weeks of discontinuation [22]. Read together, the pattern across all four is less about any single peptide being "safe" or "unsafe" and more about how precisely each claim maps to an actual study.

---

An investigative reading file on research peptides — every claim traced to its source, every gap named, revised whenever the record moves.